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Abstract
Inherited defects of the neuromuscular junction (NMJ) comprise an increasingly diverse range of disorders, termed
congenital myasthenic syndromes (CMS). Therapies acting on the sympathetic nervous system, including the selective b2
adrenergic agonist salbutamol and the a and b adrenergic agonist ephedrine, have become standard treatment for several
types of CMS. However, the mechanism of the therapeutic effect of sympathomimetics in these disorders is not understood.
Here, we examined the effect of salbutamol on NMJ development using zebrafish with deficiency of the key postsynaptic
proteins Dok-7 and MuSK. Treatment with salbutamol reduced motility defects in zebrafish embryos and larvae. In addition,
salbutamol lead to morphological improvement of postsynaptic acetycholine receptor (AChR) clustering and size of synaptic
contacts in Dok-7-deficient zebrafish. In MuSK-deficient zebrafish, salbutamol treatment reduced motor axon pathfinding de-
fects and partially restored the formation of aneural prepatterned AChRs. In addition, the effects of salbutamol treatment
were prevented by pre-treatment with a selective b2 antagonist. Treatment with the cyclic adenosine monophosphate
(cAMP) activator forskolin, replicated the effects of salbutamol treatment. These results suggest that sympathomimetics exert
a direct effect on neuromuscular synaptogenesis and do so via b2 adrenoceptors and via a cAMP-dependent pathway.
†
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Introduction
The development of the neuromuscular junction (NMJ) requires
several levels of organization, and occurs in a series of overlap-
ping steps which require interplay between presynaptic nerves
and postsynaptic muscle components. NMJs assemble in a nar-
row central region of the myofibre, where the density of acetyl-
choline receptors (AChRs) must be high in order to initiate a
synaptic potential (1). Prior to innervation, in the step termed
prepatterning, clusters of AChRs localize in a central band on
muscle fibres (2). Several intrinsic muscle proteins are required
for this process including the muscle-specific receptor tyrosine
kinase (MuSK) and the low-density lipoprotein receptor-related
protein-4 (LRP4) (3,4). Following innervation, some of these pre-
patterned AChR clusters are actively incorporated into develop-
ing NMJs, supporting the view that the postsynaptic apparatus
defines its central region for ingrowing motor axons (5). The ar-
riving motor nerve, and the agrin released by it, subsequently
stabilize the AChR clusters and cause the dispersal of non-
synaptic AChR clusters (6). Agrin binds the preformed MuSK/
LRP4 complex to initiate MuSK autophosphorylation and activa-
tion, thereby initiating a cascade of signalling pathways leading
to AChR clustering and postsynaptic differentiation (7,8). MuSK
also recruits the adaptor protein Downstream of Kinase-7
(Dok-7), which stimulates further MuSK phosphorylation (9,10).
Thus, the LRP4/MuSK/Dok-7 agrin receptor complex is indis-
pensable for tyrosine phosphorylation and clustering of AChRs.
Components of the LRP4/MuSK/Dok-7 complex are the tar-
gets of mutations responsible for subsets of congenital myas-
thenic syndromes (CMS), which are characterized by fatigable
muscle weakness (11). CMS are one of the few neuromuscular
diseases for which symptomatic treatments are readily avail-
able. For many subtypes, clinical benefit is gained from admin-
istration of acetylcholinesterase (AChE) inhibitors, which
augment the synaptic response to acetylcholine. For other CMS
subtypes, including those with mutations that cause deficits in
Dok-7, MuSK, and in end-plate AChE deficiency, the sympatho-
mimetics ephedrine and salbutamol are first-line treatment.
These drugs lead to increasing and sustained improvements in
muscle strength, with the effect peaking after 3–6 months of
commencing treatment (12–14). However, the mechanism by
which these drugs may alter neuromuscular transmission in
these patients is not known.
In order to address this, we examined the effects of the b2
agonist salbutamol on NMJ development in zebrafish. There are
several factors which make zebrafish a useful model system to
study synaptogenesis. NMJ development occurs in a similar se-
ries of steps in zebrafish as in mammals, with a diffuse elon-
gated band of prepatterned AChRs forming in the central region
of adaxial muscle fibres prior to the arrival of the motor growth
cone (5). The first NMJs are formed between 16 and 24 h post fer-
tilization (hpf) and by 120 hpf synapses are localized at the end
of muscle fibres (the vertical myosepta) and scattered over the
entire length of muscle fibres (15,16). The speed at which the
neuromuscular system develops has allowed the consequences
of deficiency of key synaptic proteins which would be lethal in
mammals to be examined in zebrafish before death occurs, in-
cluding functional knockouts of AChRs, AChE, MuSK, Rapsyn
and Dok-7 (17–21).
Here, we use antisense morpholino oligonucleotides (MO)
which knockdown expression of two key postsynaptic proteins,
Dok-7, which leads to impaired motility and smaller NMJs, and
unplugged, the zebrafish orthologue of MuSK, which demon-
strates aberrant motor axon pathfinding and impaired AChR
prepatterning (19,21,22). We show that salbutamol leads to im-
provement in AChR clustering, motor axon guidance and the
development of prepatterned AChR clusters, as well as having
functional benefit on motility and swim behaviour in zebrafish
embryos. In addition, we show that the primary effect of salbu-
tamol on NMJ development is mediated via b2 receptors and via
the cyclic adenosine monophosphate (cAMP)/protein kinase A
(PKA) pathway. Our results suggest that b2 agonists directly in-
fluence synaptic organization and that their therapeutic benefit
in myasthenic disorders may be through morphological restora-
tion of the NMJ.
Results
Salbutamol treatment of Dok-7 morphant zebrafish
improves motility and synaptogenesis
In zebrafish, knockdown of NMJ proteins usually affects motility
and swimming behaviour. The first locomotor behaviour stage
observed is spontaneous alternating tail movements inside the
chorion from 17 hpf. Dok-7 MO-injected embryos perform these
at a reduced frequency to wild-type (WT) embryos, when mea-
sured at 24 hpf (21). Following 24 h of salbutamol treatment,
Dok-7 embryos performed these tail twists at an increased fre-
quency compared with untreated Dok-7 embryos (Fig. 1A,
P< 0.01). After hatching from the chorion, zebrafish embryos re-
spond to touch stimulus rapidly by swimming away from the
stimulus. Approximately 50% of Dok-7 embryos demonstrate an
abnormal response to touch stimuli, and may make abnormal
twitching movements or fail to move away from the stimulus
(21). Following salbutamol treatment, an increased percentage
of Dok-7 embryos demonstrated normal swimming behaviour
following touch stimuli (Fig. 1B, P< 0.01).
The morphology of the NMJ was examined in the Dok-7 zebra-
fish by immunostaining of AChRs and presynaptic nerve termi-
nals (Fig. 2A). Although Dok-7 zebrafish lack prepatterned AChR
clusters, they do subsequently develop AChR clusters opposed to
the growth cone along the horizontal midline of each myotome
(the horizontal myoseptum). In Dok-7 embryos, this area of pre-
and postsynaptic co-localization is smaller than in WT embryos.
We calculated the area of co-localization following salbutamol
treatment as a percentage of the area of the myotome it occupied.
Following salbutamol treatment, the area of co-localization on
the horizontal myoseptum increased significantly (Fig. 2B, 6.2% in
treated Dok-7 embryos, compared with 5.5% in untreated Dok-7
embryos, P< 0.01). In addition, the number of AChR clusters
larger than 20 lm2 on myotomal muscle fibres increased follow-
ing salbutamol treatment (Fig. 2C, mean number of AChR clusters
per myotome 2.9 in treated Dok-7 embryos, compared with 1.49
in untreated Dok-7 embryos, P< 0.0001).
Salbutamol treatment alleviates axon pathfinding
defects in zMuSK zebrafish
The results of salbutamol treatment in the Dok-7 zebrafish
prompted us to explore the effect of salbutamol on NMJ devel-
opment when another key postsynaptic protein was knocked
down. We studied the effect of salbutamol in unplugged mor-
phants, the zebrafish homologue of MuSK. Unplugged has
two splice variants; splice variant 1 (SV1) which has a role in
AChR prepatterning and axon guidance, and splice variant 2
(full-length, FL) which is dispensable for both of these processes
(19,22). We used a MO targeting only the unplugged SV1
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isoform (19). Unplugged SV1 transcripts are first detectable at 10
hpf and expression is restricted to adaxial muscle cells until
late somitogenesis (>24 hpf) when it is downregulated to coin-
cide with the arrival of motor growth cones and lateral migra-
tion of adaxial cells, thus embryos were examined in the first 24
hpf (19). We refer to zebrafish embryos with MO knockdown of
unplugged SV1 as zMuSK.
In zebrafish, each myotomal muscle is initially innervated
by just three primary motor neurons, termed CaP, MiP and RoP
(16). Initially, all three motor growth cones extend along the me-
dial surface toward a ‘choice point’ on the horizontal myosep-
tum (16,23). Here, growth cones pause and make contacts with
muscle cells, and then select a specific path to ventral, dorsal or
medial myotomal regions.
In contrast to WT embryos, zMuSK embryos display charac-
teristic stalling and branching at the choice point, even though
their dorsal adaxial cells are properly specified and migrate cor-
rectly (19). Following treatment with salbutamol, zMuSK MO-in-
jected embryos displayed a restoration of axonal pathfinding
defects at 24 hpf (Fig. 3A and B); in untreated embryos, 51%
(n¼ 123/240) of imaged somites displayed axons which failed to
cross the midline at 24 hpf, compared with 14% (n¼ 34/240) in
embryos treated with salbutamol (P< 0.0001). In addition, zMuSK
knockdown causes complete absence or greatly reduced numbers
of AChRs at 24 hpf. In zMuSK MO embryos treated with salbuta-
mol, however, AChR clusters could be seen as a band on the hori-
zontal myotome at 24 hpf (Fig. 3C and D), which was similar
although not as organized as the band seen in WT embryos.
In order to ascertain whether salbutamol treatment had an ef-
fect on the formation of prepatterned AChR clusters, we examined
the caudal segments of embryos at 17 hpf for the presence of
AChR clusters prior to the arrival of the motor growth cone. In sal-
butamol-treated embryos, a partial rescue of the formation of pre-
patterned AChR cluster formation was observed (Fig. 3E and F).
The effects of salbutamol on NMJ development are via
the b2 receptor
In order to ascertain whether the effects seen following salbuta-
mol treatment were due to its action as a b2 agonist, or via an
off-target effect, we pre-treated zebrafish embryos with the se-
lective b2 antagonist ICI118, 551. Following 3 h of pre-treatment
with this b2 blocker, the addition of salbutamol failed to have
the same effect on motor axon growth cones (Fig. 4), indicating
that the effects observed are mediated via b2 receptors.
The effects of salbutamol on NMJ development are via
the cAMP signalling pathway
Agonist activation of b2 adrenoceptors stimulates a cascade of
intracellular signalling pathways, with the most prolific being
the cAMP/PKA pathway. Following b2-adrenoceptor stimula-
tion, the receptor couples to the Gas subunit and activates ade-
nylate cyclase, generating cAMP. However, several additional
pathways which are Gas-independent can also be activated by
b2-adrenoceptors binding (24). In order to ascertain whether the
downstream signalling pathway involved in rescue of the NMJ
morphology in zebrafish was via cAMP or via a Gas-independent
pathway, we treated zebrafish embryos with the adenylyl
cyclase activator forskolin. Following incubation for 24 h with
5lM forskolin, the effects of salbutamol axon pathfinding
(Fig. 5A and B) and AChR clustering (Fig. 5C) in zMuSK embryos
were replicated. In addition, forskolin treatment lead to an in-
crease in the number of prepatterned AChR clusters (mean 3.5
prepatterned clusters per myotome in forskolin-treated em-
bryos, compared with 0.5 in untreated embryos, P< 0.0001).
Discussion
The process of neuromuscular transmission is complex and in-
volves several levels of specialization. There are numerous cel-
lular and molecular pathways which may be potential
pathological or therapeutic targets. Given that b2 adrenoceptors
activate many signalling pathways linked to a variety of
changes in different tissues and cell types, the mechanisms of
improved neurotransmission by b-agonists may be numerous,
and may include postsynaptic expansion of end plates, growth
of presynaptic nerve terminals or restoration of normal levels of
neurotransmitter release. Zebrafish models allow the analysis
of the effect of b-agonists during each step of NMJ development,
Figure 1. Dok7 morphant zebrafish demonstrate improved motility in the presence of salbutamol. (A) When monitored at 24 hpf, Dok7 MO-injected embryos are able to
perform tail twisting movements in their chorion but do so at lower frequency than WT embryos. Following salbutamol treatment, Dok7 embryos performed tail twists
at an increased frequency (mean 6.1 per 60 s) compared with untreated embryos (mean 4.6 per 60 s). A total of 30 embryos were observed for each category. ** indicates
P<0.01, Student’s t-test, n ¼30 treated and 30 untreated embyros observed. (B) Dok7 embryos demonstrate equal percentages of normal and abnormal touch-evoke re-
sponse (TER) to stimuli at 48 hpf. Embryos treated with salbutamol demonstrate an increased percentage of normal swim behaviour. ** indicates P< 0.01, chi-square
test, n¼3 tests on 30 embryos were performed for each category. All error bars depict S.E.M.
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which in turn may give some indication as to which molecular
mechanisms may be involved, based on the previously charac-
terized role of key NMJ proteins at each of these steps. We ob-
served that salbutamol treatment led to morphological
improvement of the NMJ at several developmental steps: an
increase in the area of co-localization of presynaptic nerve ter-
minals and AChR clusters on the horizontal myoseptum in Dok-
7 MO-injected embryos, improvement in AChR clustering at in
Dok-7 MO-injected embryos, rescue of the axonal pathfinding
defects in zMuSK MO-injected embryos and improvement in
Figure 2. Salbutamol treatment of Dok-7 MO-injected zebrafish improves NMJ morphology. Lateral views of 48 hpf embryos with neuromuscular synapses labelled
with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. (A) In Dok7 MO-injected embryos, the focal innervation
point along the horizontal myoseptum is reduced in size compared with wild type, but is increased following treatment with 20 mM salbutamol (arrows). In addition,
the morphology of myoseptal (boxes) and myotomal (asterisks) AChR clusters is partially rescued with salbutamol treatment. A representative 20 lm2 AChR cluster is
labelled with a bracket. (B) Following salbutamol treatment, the area of synaptic contact on the horizontal myoseptum is significantly increased (** indicates P<0.01,
Student’s t-test, n ¼160 treated and 160 untreated myotomal segments examined). (C) Salbutamol treatment caused a significant increase in the number of AChR clus-
ters>20 lm2 per myotome in Dok7 zebrafish embryos (**** indicates P<0.0001, Student’s t-test, n ¼100 treated and 100 untreated myotomal segments examined).
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the formation of prepatterned AChR clusters. We did not ob-
serve an improvement in the number of prepatterned AChR in
Dok-7-deficient zebrafish (data not shown). This is unexpected,
given the known function of the MuSK/Dok-7 complex at the
NMJ, and it is possible that changes in expression of prepat-
terned AChR in the Dok-7 MO-injected embryos may have been
too small to be detected as changes on immunostaining. In ad-
dition, we observed that the adenylyl cyclase activator forskolin,
lead to dramatic improvements in axonal pathfinding and
AChR clustering, and improved AChR prepatterning in zMuSK
zebrafish.
Each of these steps are governed primarily by muscle-de-
rived signals in zebrafish (19,25). This is in-keeping with the fact
that it is mainly postsynaptic CMS subtypes in which the effect
of b-agonist therapy is beneficial. Salbutamol treatment leads to
an increasing and sustained response in Dok-7 CMS (13).
Although the pathomechanisms of Dok-7 CMS are not yet fully
understood, it is widely accepted that mutations in DOK7 impair
Dok-7’s ability to activate MuSK. This assumption is supported
by the fact that many mutations in Dok-7 CMS target the COOH
terminal, phosphotyrosine binding (PTB) or pleckstrin homology
(PH) domains, which are critical sites for activation of MuSK in
Figure 3. Salbutamol treatment of zMuSK MO-injected embryos improves motor axon pathfinding defects and AChR clustering. Lateral views of embryos with neuro-
muscular synapses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bars¼10 mm. (A) zMuSK MO-injected
embryos at 24 hpf demonstrate characteristic stalling of the outgrowing motor axon at the choice point on the horizontal midline (arrow). Following salbutamol treat-
ment more axons cross the horizontal midline and extend to the periphery of the myotome (double arrow). (B) Quantification of the improvement of motor axon
growth following salbutamol treatment. (**** indicates P<0.0001, chi-square test, n¼240 treated and 240 untreated myotomal segments examined). (C) zMuSK embryos
at 24 hpf display almost complete absence of AChR clustering. In salbutamol-treated zMuSK embryos, AChR clustering is restored. (D) Quantification of the improve-
ment in AChR clustering following salbutamol treatment of zMuSK embryos. AChR clustering is significantly increased with the mean number of AChR clusters>20
lm2 per myotome 1.16 in salbutamol treated embryos compared with 0.64 in untreated embryos (**** indicates P<0.0001, Student’s t-test, n¼ 100 treated and 100
untreated myotomal segments examined). (E) zMuSK MO-injected embryos at 17 hpf. Untreated embryos lack elongated, diffuse prepatterned clusters on the myoto-
mal surface prior to the arrival of the motor growth cone (boxed areas), but following salbutamol treatment some zMuSK embryos display prepatterned clusters.
(F) Quantification of the effect of salbutamol on prepatterned AChR clustering in zMuSK embryos. Following salbutamol treatment, the number of prepatterned AChR
clusters>3 lm2 in zMuSK embryos increased, with a mean of 0.5 prepatterned clusters per myotome in untreated embryos, compared with 1.3 in salbutamol-treated
embryos (* indicates P<0.05, Student’s t-test, n¼30 untreated and 30 untreated myotomal segments examined).
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vitro and in vivo (26,27). The other CMS subtype in which treat-
ment with b agonists leads to consistent improvement is CMS
due to end-plate AChE deficiency, which is caused by mutations
in COLQ (28,29). In addition to its role in anchoring AChE in the
basal lamina, the C-terminus domain of ColQ binds MuSK, and
ColQ has been shown to have an important regulatory role in
postsynaptic differentiation through this interaction (30). The
pathology of Dok-7 and ColQ CMS subtypes may be unified by
the role of both proteins in postsynaptic specialization and
AChR clustering. b agonist therapy may therefore also play a
role in postsynaptic differentiation in mammals. Indeed, sev-
eral lines of evidence point toward cAMP/PKA-dependent path-
ways involved in metabolic stabilization of AChRs (31–33).
The effect of salbutamol on both axonal pathfinding and
number of prepatterned AChR clusters in zebrafish indicates a
possible role for b2 agonists in upregulation or activation of a
MuSK-dependent pathway in early synapse development,
which has been previously shown to be indispensable for nor-
mal regulation of both of these processes in zebrafish (19).
There are several potential pathways by which b2-adrenergic
agonist-mediated activation of the cAMP/PKA pathway could be
activating MuSK, including the b-catenin/Wnt signalling path-
way. The zebrafish homologue of MuSK has been previously
shown to interact with Wnt11r to restrict AChR prepattern in a
central muscle zone (22), in a similar manner to the interaction
with Wnt signalling and mammalian MuSK (34). However, given
that salbutamol and forskolin treatment led to only partial res-
cue of the motility and NMJ defects in our zebrafish models, it is
conceivable that additional pathways not upregulated by cAMP
signalling are also involved.
The effects of forskolin on the NMJ not only indicate the cAMP
mimetic action of salbutamol at the NMJ, but also were even more
marked than those observed following salbutamol exposure. This
more obvious effect may reflect increased absorption, bioavailabil-
ity or efficacy of forskolin compared with salbutamol in zebrafish.
Forskolin has been used in several clinical settings including
asthma, congestive cardiomyopathy and obesity (35–37). However,
its efficacy in neuromuscular disease is unknown. One possible
role for forskolin could be in the treatment of CMS patients who
have become tolerant to the effect of beta-adrenergic receptor
stimulation following many years of treatment, given that its
mechanism of action is receptor independent. Further preclinical
studies will be required to confirm these findings.
We accept there are limitations to our disease models. Whilst
treatment of zebrafish embryos provides a model for NMJ forma-
tion and exploring the role of b2 agonists in this process, effects
can only be studied over a short treatment period. The therapeu-
tic effect of b agonists seen in CMS patients is a delayed one, with
an increasingly positive response after many months of treat-
ment (13). The relatively short exposure duration of the zebrafish
Figure 4. Pre-treatment with a selective b2 antagonist blocks the rescue of NMJ development by salbutamol. Lateral views of 24 hpf embryos with neuromuscular syn-
apses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. zMuSK embryos were treated with 5 mM
of the selective b2 antagonist ICI118, 551 or control (water) added to E3 medium for 3 h prior to the addition of 20 mM salbutamol. (A) In zebrafish embryos pre-treated
with ICI118, 551 no rescue of the axonal pathfinding defects was seen following 21 h of salbutamol treatment, with stalling and branching of motor growth cones (as-
terisks). (B) Quantification of the effect of pre-treatment of ICI118, 551 on motor axon growth. Following pre-treatment with 5 mM ICI118, 551, salbutamol treatment did
not have an effect on axon pathfinding (n.s. P>0.05, ****P<0.0001, chi-square test, n¼240 treated and 240 untreated myotomal segments examined).
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to salbutamol and forskolin may further explain why only a par-
tial rescue of the phenotype was observed in both models. In ad-
dition, patients with CMS due to DOK7 mutations frequently
present after infancy or in early adulthood (38), and postnatal
knockdown of Dok-7 gene expression has been shown to cause
CMS in mice (39), indicating a further role for Dok-7-mediated ac-
tivation of MuSK in postnatal NMJ maintenance. Therefore, it is
possible that the improvement seen in b-agonist-treated CMS pa-
tients is due to an additional role they play in NMJ homeostasis.
This hypothesis is supported by the recent finding of sympathetic
innervation in close contact with the NMJ contributing toward
NMJ maintenance (32). Further work will be in identifying the
mechanism of altered postsynaptic specialization by either en-
dogenous or exogenous b2-adrenoceptor ligands and cAMP acti-
vation. Nevertheless, the effects demonstrated during NMJ
development in these zebrafish models, indicate that sympatho-
mimetics may alter the regulation of key NMJ signalling mole-
cules, and suggest that b2 agonists illicit their therapeutic effect
in myasthenic disorders through a direct effect at the NMJ.
Materials and Methods
Zebrafish husbandry
The Golden strain (slc24a5b1/þ) of zebrafish was used (Zebrafish
International Resource Centre, Oregon). Zebrafish embryos were
raised in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4, 0.01% methylene blue) at 28.5C and staged in
hours post fertilization (hpf) according to standard protocols.
Phenotype and motility observation
Tail twists in chorion at 24 hpf were measured by observing
each embryo for 60 s and counting total number of complete
twists. A total 30 embryos were measured for each category.
Touch-evoked swimming response (TER) was observed by
touching the head or tail of the zebrafish with a fine pipette tip.
TER was defined as abnormal if embryos exhibited either cir-
cling movements, twitching with no movement away from the
stimulus, or had no movement at all as a response. At least 20
embryos were observed for each category and the experiment
was repeated five times.
Antisense morpholino oligonucleotide knockdown
Antisense MO were injected into the yolk of one-to-two cell
stage embryos. Dok-7 embryos were injected with 15 ng of Dok-
7 MO. MuSK embryos were injected with 5 ng of zMuSK MO. In
addition, control MOs were injected at the same concentration
for each injection experiment. MOs were purchased from Gene
Tools LLC (Pilomath, OR). A splice-blocking MO was used to tar-
get Dok-7 transcripts at exon 2: 50-ATTTATAGGATTTACCTG
CTACCGG. This splice-blocking MO causes skipping of the exon
and premature translation termination through targeting of the
splice donor site of exon 2 (21). For MuSK experiments, a MO tar-
geting the unplugged splice transcript variant 1 (unplugged/
SV1) was used (19,22): 50-GTAGAGGATTACCGTATTGCCGTT.
This causes skipping of exon 2, frameshift and a premature stop
codon after 24 cryptic residues. The Gene Tools standard control
MO (50-CCTCTTACCTCAGTTACAATTTATA-30) targeting a hu-
man beta-haemoglobin gene was used as a negative control.
MOs were suspended in 1 Danieau buffer (58 mM NaCl, 0.7 mM
KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES; pH 7.6) with
phenol red as an injection indicator. At least two independent
MO injection experiments were performed for each MO and
200–800 injected embryos were evaluated for each treatment
regimen.
Treatment of zebrafish with salbutamol, ICI118, 551 and
forskolin
Zebrafish embryos were raised post injection in E3 medium con-
taining the compounds or control vehicle. We conducted
Figure 5. The effects of b2 receptor agonist activation on NMJ morphology are replicated by cAMP activation. Lateral views of 24 hpf embryos with neuromuscular syn-
apses labelled with antibodies against SV2 (green, presynaptic vesicles) and aBTX (red, postsynaptic AChRs). Scale bar¼50 mm. (A) zMuSK embryos at 24 hpf demon-
strate improvement in AChR clustering and axon pathfinding defects following forskolin treatment. (B) Quantification of motor axon guidance defects. About 88%
(n¼28/240) of imaged somites of zMuSK embryos treated with forskolin displayed no axon guidance defects, compared with 41% (n¼ 142/240) of those in untreated
zMuSK embryos. **** indicates P<0.0001, chi-square test. (C) The number of AChR clusters larger than 20 lm2 on myotomal muscle fibres increased with forskolin treat-
ment, with mean number of clusters 0.39 per myotome in untreated embryos, and 1.48 in treated zMuSK embryos. **** indicates P<0.0001, Student’s t-test, n¼100
treated and 100 untreated myotomes examined.
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preliminary dose response testing for salbutamol (1, 10, 20 and
50 mM), forskolin (0.1, 1, 3, 5 and 10 mM) and ICI118, 551 (1, 3, 5, 20
and 50 mM). Concentrations of 20 mM salbutamol, 5 mM forskolin
and 5 mM ICI118, 551 resulted in strong effects and limited toxic-
ity, and these concentrations were selected for all further exper-
iments. For salbutamol treatment, embryos were exposed to 20
mM concentration of salbutamol (Sigma) or 20 mM of methanol for
up to 72 hpf. For pre-treatment with the selective b2 receptor
blocker ICI118, 551, zebrafish embryos were incubated with E3
medium containing either 5 mM of ICI118, 551 hydrochloride
(abcam) or 5 mM of distilled water. After 3 h, 20 mM of salbutamol
was added to the same E3 medium. For forskolin treatment,
zebrafish embryos were raised in E3 medium containing 5 mM of
forskolin (abcam) or 5 mM ethanol for up to 72 hpf.
Zebrafish whole-mount immunofluorescence staining
Embryos were fixed in 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) overnight and then permeabi-
lized in cold acetone at 20C. Depending on their age, 3–5
days post fertilization old larvae were permeabilized with col-
lagenase A (Roche Diagnostics, 1 mg/ml) for 60 min. Embryos
were blocked in 5% horse serum in PBS 0.1% Tween-20 (PBS-T).
Embryos were incubated in 5% horse serum in PBS-T contain-
ing primary antibody overnight at 4C (presynaptic nerve ter-
minals: SV2, 1: 200 from Developmental Studies Hybridoma
Bank, Iowa), washed several times with PBS-T and incubated
with secondary antibody (goat anti-mouse Alexa Fluor 488,
donkey anti-mouse Alexa Fluor 594, goat ant-rabbit Alexa
Fluor 680, all Invitrogen). AChRs were visualized by using
Alexa Fluor 594-conjugated a-bungarotoxin (1 lg/ml,
Invitrogen). Immunofluorescence staining was imaged using a
Nikon confocal microscope (Nikon A1R Invert). For quantifica-
tion of NMJ morphological changes, 30 embryos were imaged
for each category. Because of the rostral-to-caudal gradient of
embryonic development in zebrafish, we used the same myo-
tomal segments for comparison, by examining the five myo-
tomes centred around the caudal-most part of the yolk
extension. WT, untreated morphant and treated morphant tis-
sues were processed for immunofluorescence in parallel and
images were acquired with the same confocal microscopy set-
tings (laser power, gain, magnification and Z-stack interval).
Image analysis was performed using ImageJ software.
Immunostained structures were counted as NMJs when SV2
was opposed to a-bungarotoxin with at least 50% co-localiza-
tion. The outer perimeter of each area of co-localization on the
horizontal myoseptum was drawn by hand and the enclosed
area was measured. The area of each myotome was also mea-
sured, and the area of co-localization was measured as a frac-
tion of the myotome it occupied. For AChR quantification,
AChR clusters were thresholded and their area and intensity
measured, and the number AChR clusters greater than 20 lm2
in size per myotome were compared. For prepatterned AChR
quantification, the five caudal-most myotomal segments were
compared in 17 hpf embryos, and the number of AChRs greater
than 3 lm2 per myotome were quantified. Axon pathfinding
defects were quantified by counting the percentage of myo-
tomes with axons which failed to cross the horizontal midline
at 24 hpf. When comparing values from treated zebrafish with
values from untreated zebrafish an unpaired Student’s t-test
or chi-square test was used. Thresholds of P< 0.05 were con-
sidered significant. We confirmed normal distributions of data
before performing parametric tests.
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